Search
Based in 'both-way learning', the aim of this study was to co-design, implement and evaluate community-based participatory action research to achieve this vision
We outline a series of research initiatives to improve identification of RHD in administrative data thereby contributing to monitoring the RHD burden globally
Prevention strategies in ARF endemic settings may be enhanced by targeting new members entering a community and children in environments of close contact
We propose that hydroxychloroquine could be repurposed to reduce the risk of rheumatic heart disease after acute rheumatic fever
The authors present a variety of pressing clinical research questions on optimal RHD prevention and advanced care
The prevalence of impetigo and pharyngitis - which are both superficial group A streptococcus (GAS) infections that precede acute rheumatic fever - is poorly defined. Guidelines recommend the early diagnosis of both infections to prevent ARF; however, screening to enable the concurrent detection of these infections in high-risk populations has rarely been performed.
We have read with interest the new publication by Rouhiainen and colleagues on missed opportunities for preventing or diagnosing acute rheumatic fever (ARF).
Fear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.
Although benzylpenicillin (penicillin G) is listed by the World Health Organization as an Essential Medicine, dose optimization is a persistent challenge, especially for long-acting intramuscular formulations. Maintaining sustained antibiotic exposure at target concentrations is crucial for secondary chemoprophylaxis of rheumatic heart disease and treatment of syphilis.
End RHD CRE News & Events